The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Clinical trial NCT05431504 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05431504
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-01
- Primary completion
- 2025-12-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.